Immuno-oncology Sensei Biotherapeutics’ SNS-103 shows pH-dependent antitumor efficacy Sep. 19, 2024 Work at Sensei Biotherapeutics Inc. has led to the discovery of an anti-CD39 antibody dependent on pH in the TME, SNS-103.Read More
